Infectious Disease Clinics of North America volume 26, issue 4, P903-915 2012 DOI: 10.1016/j.idc.2012.08.008 View full text
|
|
Share
Jennifer A. Flemming, Norah A. Terrault

Abstract: A significant proportion of treatment-experienced hepatitis C virus genotype 1 (GT1) patients will not achieve sustained virologic response [corrected] with protease inhibitor-triple therapy, and so the need for alternative therapies for these patients remains high. The aim of this article is to provide a critical evaluation of the available data, highlighting the knowledge gaps and providing a practical framework for making treatment decisions in treatment-experienced GT1 patients with currently approved drug…

expand abstract